🏛️ Verified NIH Record • Updated 2022-03-28
Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors (NCT03836352)
A Phase 2, Open-label, Multicenter, Study of an Immunotherapeutic Treatment, DPX-Survivac in Combination With Low Dose Cyclophosphamide and Pembrolizumab, in Subjects With Selected Advanced and Recurrent Solid Tumours.
🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: ImmunoVaccine Technologies, Inc. (IMV Inc.)
🩺 Plain-English Summary (8th-Grade Level)
This study will assess the safety and efficacy of DPX-Survivac and low dose cyclophosphamide with pembrolizumab in subjects with selected advanced and recurrent solid tumours.
Who can join: Review the eligibility criteria below.
Location: The University of Arizona Cancer Center — Tucson, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (23 Sites)
- The University of Arizona Cancer Center — Tucson, Arizona
- Cedars Sinai Medical Center: Samuel Oschin Comprehensive Cancer Center — Los Angeles, California
- Boca Raton Regional Hospital, Lynn Cancer Institute — Boca Raton, Florida
- Hematology Oncology Associates of the Treasure Coast — Port Saint Lucie, Florida
- Comprehensive Hematology and Oncology — St. Petersburg, Florida
- Winship Cancer Institute: The Emory Clinic — Atlanta, Georgia
- James Brown Graham Cancer Center:University of Louisville Hospital — Louisville, Kentucky
- Ochsner Cancer Institute — New Orleans, Louisiana
- Allina Health, Virginia Piper Cancer Institute — Minneapolis, Minnesota
- Christus St. Vincent Regional Cancer Center — Santa Fe, New Mexico
- NYU Winthrop Hospital — Mineola, New York
- Montefiore Medical Center — The Bronx, New York
- University of Toledo — Toledo, Ohio
- Mary Crowley Cancer Research Center — Dallas, Texas
- MD Anderson — Houston, Texas
- William Osler Health System — Brampton, Ontario
- Juravinski Cancer Center — Hamilton, Ontario
- Southlake Regional Health Center — Newmarket, Ontario
- The Ottawa Hospital — Ottawa, Ontario
- Sunnybrook Research Institute — Toronto, Ontario
- Centre hospitalier de l'Université de Montréal (CHUM) — Montreal, Quebec
- McGill University Health Center — Montreal, Quebec
- CHU de Québec-Université Laval — Québec, Quebec
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Ovarian Cancer
- Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy — New York, New York
- Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer — Pittsburgh, Pennsylvania
- Trial on Radical Upfront Surgery in Advanced Ovarian Cancer — New York, New York
- Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC) — Duarte, California
- Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302) — Little Rock, Arkansas
- NeoVax With Nivolumab in Patients With Ovarian Cancer — Boston, Massachusetts
Explore by condition: All Ovarian Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.